公开(公告)号：US12128013B2

公开(公告)日：2024-10-29

申请号：US18236795

申请日：2023-08-22

申请人： Aldeyra Therapeutics, Inc.

发明人： Todd Brady ,  Scott Young ,  William A. Kinney ,  Kenneth J. Mandell

IPC分类号： A61K31/137 ,  A61K8/41 ,  A61K8/44 ,  A61K8/49 ,  A61K31/13 ,  A61K31/197 ,  A61K31/423 ,  A61K31/435 ,  A61K31/438 ,  A61K31/47 ,  A61Q19/00 ,  A61Q19/08 ,  C08K5/04 ,  C08K5/08 ,  C08K5/18

CPC分类号： A61K31/137 ,  A61K8/41 ,  A61K8/44 ,  A61K8/49 ,  A61K8/4926 ,  A61K31/13 ,  A61K31/197 ,  A61K31/423 ,  A61K31/435 ,  A61K31/438 ,  A61K31/47 ,  A61Q19/00 ,  A61Q19/08 ,  C08K5/04 ,  C08K5/08 ,  C08K5/18

摘要： The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

公开(公告)号：US12097188B2

公开(公告)日：2024-09-24

申请号：US18241598

申请日：2023-09-01

申请人： Aldeyra Therapeutics, Inc.

发明人： Thomas A. Jordan ,  John Clifford Chabala ,  Gerald D. Cagle

IPC分类号： A61K31/423 ,  A61K9/00 ,  A61K31/47 ,  A61K47/40

CPC分类号： A61K31/423 ,  A61K9/0048 ,  A61K31/47 ,  A61K47/40

摘要： The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.

公开(公告)号：US12077542B2

公开(公告)日：2024-09-03

申请号：US17662246

申请日：2022-05-06

申请人： Ikena Oncology, Inc.

发明人： Alfredo C. Castro ,  Catherine A. Evans

IPC分类号： C07D487/04 ,  A61P29/00 ,  A61P35/00 ,  C07D401/14 ,  C07D473/34 ,  C07D495/04 ,  C07D519/00 ,  A61K9/00

CPC分类号： C07D487/04 ,  A61P29/00 ,  A61P35/00 ,  C07D401/14 ,  C07D473/34 ,  C07D495/04 ,  C07D519/00 ,  A61K9/0053

摘要： The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

公开(公告)号：US12064516B2

公开(公告)日：2024-08-20

申请号：US17333528

申请日：2021-05-28

申请人： Aldeyra Therapeutics, Inc.

发明人： Todd Brady ,  Adam Brockman ,  Stephen Gitu Machatha

IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K9/16 ,  A61K9/48 ,  A61K31/47 ,  A61P11/00

CPC分类号： A61K9/1623 ,  A61K9/0053 ,  A61K9/1611 ,  A61K9/1635 ,  A61K9/1652 ,  A61K31/47 ,  A61P11/00 ,  A61K9/20 ,  A61K9/48

摘要： The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseases, organ diseases, viral infections, and sequelae and associated conditions such as acute respiratory distress syndrome.

公开(公告)号：US12064486B2

公开(公告)日：2024-08-20

申请号：US16798890

申请日：2020-02-24

申请人： HOMOLOGY MEDICINES, INC.

发明人： Albert Barnes Seymour ,  Seemin Seher Ahmed ,  Jason Boke Wright ,  Serena Nicole Dollive ,  Hillard Rubin

IPC分类号： C12N15/864 ,  A61K38/43 ,  A61K48/00 ,  C12N15/11 ,  C12N15/52 ,  C12N15/86

CPC分类号： A61K48/0066 ,  C12N15/86 ,  C12N2750/14143 ,  C12N2750/14152 ,  C12N2750/14171 ,  C12N2830/32

摘要： Provided herein are adeno-associated virus (AAV) compositions that can express a phenylalanine hydroxylase (PAH) polypeptide in a cell, thereby restoring the PAH gene function. Also provided are methods of use of the AAV compositions, and packaging systems for making the AAV compositions.

公开(公告)号：US12049520B2

公开(公告)日：2024-07-30

申请号：US17648560

申请日：2022-01-21

申请人： BicycleTx Limited

发明人： Liuhong Chen ,  Rachid Lani ,  Kevin McDonnell ,  Gemma Elizabeth Mudd ,  Peter Park

IPC分类号： A61K38/00 ,  A61K47/64 ,  C07K7/64

CPC分类号： C07K7/64 ,  A61K47/64 ,  A61K38/00

摘要： The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.

公开(公告)号：US12030949B2

公开(公告)日：2024-07-09

申请号：US16966237

申请日：2019-02-15

申请人： argenx BV

发明人： Christophe Blanchetot ,  Marie Godar ,  Bart Lambrecht

IPC分类号： C07K16/18 ,  C07K16/24 ,  C07K16/28

CPC分类号： C07K16/2866 ,  C07K16/244 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

摘要： The present invention relates to combination therapies and to their use in the treatment of chronic airway disease, particularly use in the treatment of asthma. The combination therapies comprise (i) an antagonist of IL-5:IL-5R and (ii) an antagonist of IL-4:IL-4R and/or an antagonist of IL-13:IL-13R. The present invention also provides bispecific antibodies comprising an antigen binding domain that binds to IL-4Rα and an antigen binding domain that binds to IL-5. The bispecific antibodies may be used for the treatment of chronic airway disease, particularly asthma.

公开(公告)号：US12006329B2

公开(公告)日：2024-06-11

申请号：US17890847

申请日：2022-08-18

申请人： Kymera Therapeutics, Inc.

发明人： Nello Mainolfi ,  Nan Ji ,  Arthur F. Kluge

IPC分类号： C07D495/14 ,  C07D401/12 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04

CPC分类号： C07D495/14 ,  C07D401/12 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04

摘要： The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.

公开(公告)号：US11994525B2

公开(公告)日：2024-05-28

申请号：US18193357

申请日：2023-03-30

申请人： KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

发明人： Atsushi Shimada

IPC分类号： G01N33/92 ,  G01N33/487

CPC分类号： G01N33/92 ,  G01N33/48721

摘要： A membrane protein analysis substrate including an electron microscope grid having a plurality of through-holes; a lipid bilayer membrane that is provided to cover at least one of the plurality of through-holes; and membrane proteins that are retained in a part planarly overlapping the through-holes of the lipid bilayer membrane, wherein the lipid bilayer membrane has a lipid monolayer, and wherein the lipid monolayer is larger than the through hole in a plan view, adheres to the grid, and constitutes a part of the lipid bilayer membrane.

公开(公告)号：US11965174B2

公开(公告)日：2024-04-23

申请号：US17815065

申请日：2022-07-26

申请人： City of Hope

发明人： Saswati Chatterjee ,  Laura Jane Smith ,  Kamehameha Wong

IPC分类号： C12N15/86 ,  A61K35/761 ,  A61K48/00 ,  C07K14/005 ,  C12N7/00 ,  C12N7/01 ,  C12N15/10 ,  C12N15/113 ,  C12N15/90

CPC分类号： C12N15/907 ,  A61K48/0008 ,  A61K48/005 ,  C07K14/005 ,  C12N7/00 ,  C12N15/102 ,  C12N15/86 ,  A61K48/00 ,  C12N2710/16622 ,  C12N2750/14121 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N2750/14145 ,  C12N2750/14152 ,  C12N2750/14171 ,  C12N2800/70 ,  C12N2840/44

摘要： Adeno-associated virus (AAV) Clade F vectors or AAV vector variants (relative to AAV9) for precise editing of the genome of a cell and methods and kits thereof are provided. Targeted genome editing using the AAV Clade F vectors or AAV vector variants provided herein occurred at frequencies that were shown to be 1,000 to 100,000 fold more efficient than has previously been reported. Also provided are methods of treating a disease or disorder in a subject by editing the genome of a cell of the subject via transducing the cell with an AAV Clade F vector or AAV vector variant as described herein and further transplanting the transduced cell into the subject to treat the disease or disorder of the subject. Also provided herein are methods of treating a disease or disorder in a subject by in vivo genome editing by directly administering the AAV Clade F vector or AAV vector variant as described herein to the subject.